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ETATE-OF-THE-ART PAPER1057Sex-Related Differences In Myocardial Remodelingaddalena Piro, Roberta Della Bona, Antonio Abbate, Luigi M. Biasucci, Filippo Crea
yocardial remodeling is defined as the molecular and cellular events following an injury
hich lead to a change in shape, dimension, or function of the cardiac chambers. Piro and
olleagues review the experimental studies, postmortem, and observational clinical studies
hich suggest the presence of important differences in myocardial remodeling between males
nd females. These differences are found in response to different types of injures including
ging, pressure and volume overload, and myocardial infarction. In many situations, the
emodeling process appears to be more favorable in women, although the molecular effects of
strogen and other sex hormones on ventricular cardiomyocytes are not completely
nderstood.CLINICAL RESEARCH URGERY VERSUS PCI WITH DES IN DIABETICS1067CABG Versus PCI in Diabetics: Results From the SYNTAX Trial CMEdrian P. Banning, Stephen Westaby, Marie-Claude Morice, A. Pieter Kappetein, Friedrich W. Mohr,
ergio Berti, Mattia Glauber, Mirle A. Kellett, Robert S. Kramer, Katrin Leadley, Keith D. Dawkins,
atrick W. Serruys
he SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and
ardiac surgery) trial randomized 1,800 subjects to revascularization with either coronary
rtery bypass grafting (CABG) or paclitaxel-eluting stents (PES) with left main and/or 3-
essel disease. This paper compares the 1-year outcomes in the almost 500 subjects with
iabetes in the trial. The 1-year major adverse cardiac and cerebrovascular event rate
MACCE), which included revascularization, was higher in diabetic patients randomized to
ES but was similar when revascularization was not included. Compared to CABG,
ortality was higher following PES use in diabetic patients with highly complex lesions
efined by a SYNTAX score 33 (4.1% vs. 13.5%, p  0.04), although there was no
ifference in mortality when all subjects were included. This subgroup analysis can help to
dentify which diabetic patients benefit most from CABG, and which can safely undergo
ither procedure.
ditorial Comment: Harold L. Dauerman, p. 1076(continued on page A-20)
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bNTERVENTIONAL CARDIOLOGY1080TAVI for Patients at Very High or Prohibitive Surgical Riskosep Rodés-Cabau, John G. Webb, Anson Cheung, Jian Ye, Eric Dumont, Chris Feindel, Mark Osten,
adhu K. Natarajan, James L. Velianou, Giuseppe Martucci, Benoît DeVarennes, Robert Chisholm,
ark D. Peterson, Samuel V. Lichtenstein, Fabian Nietlispach, Daniel Doyle, Robert DeLarochellière,
evin Teoh, Victor Chu, Adrian Dancea, Kevin Lachapelle, Asim Cheema, David Latter, Eric Horlick
odés-Cabau and colleagues evaluated the acute and late outcomes of patients in a
omprehensive transcatheter aortic valve implantation (TAVI) program including both the
ransfemoral (TF) and transapical (TA) approaches for patients considered inoperable or at
ery high surgical risk. A total of 345 procedures (TF: 168, TA: 177) were performed. The
rocedure was successful in 93% of the cases, and procedural and 30-day mortality were 1.7%
nd 10.4%, respectively. After a median follow-up of 8 months, the cumulative mortality rate
as 22%. This TAVI program which includes both TF and TA approaches resulted in
ortality comparable to that predicted by surgical risk calculators.ditorial Comment: Bernard Iung, Dominique Himbert, Alec Vahanian, p. 1091NTERVENTIONAL CARDIOLOGY
1093-Year Outcomes of ARTS II: SES Compared to
CABG and BMS in Subjects With Multivessel Diseaseatrick W. Serruys, Yoshinobu Onuma, Scot Garg, Pascal Vranckx, Bernard De Bruyne, Marie-Claude Morice,
ntonio Colombo, Carlos Macaya, Gert Richardt, Jean Fajadet, Christian Hamm, Monique Schuijer,
essa Rademaker, Kristel Wittebols, Hans Peter Stoll, on behalf of the ARTS II Investigators
erruys and colleagues compared the 5-year clinical outcomes of sirolimus-eluting stents
SES) in the ARTS II (Arterial Revascularization Therapies Study II) with the outcomes of
oronary artery bypass graft (CABG) and bare-metal stenting (BMS) from the ARTS I.
RTS I was a randomized trial of 1,205 patients with multivessel disease comparing CABG
nd BMS, while the ARTS II was a nonrandomized trial of 607 patients using SES and the
ame inclusion and exclusion criteria, end points, and protocol definitions. At 5-year follow-
p, the death/cerebrovascular accident/myocardial infarction event-free survival rate was 92%
n ARTS II SES, versus 89% and 87% in the ARTS I CABG and BMS cohorts,
espectively. Freedom from revascularization in the ARTS II SES cohort was lower than in
RTS I CABG, but higher than in ARTS I BMS. The cumulative incidence of definite
tent thrombosis was 3.8% in ARTS II SES. At 5 years, SES had a safety record comparable
o CABG and superior to BMS; approximately one-third of the events seen with SES may
e related to stent thrombosis.(continued on page A-24)
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cIOMARKERS1102Myeloperoxidase and CRP Predict Cardiovascular Mortalitylaire L. Heslop, Jiri J. Frohlich, John S. Hill
eslop and colleagues evaluated the relative and combined value of oxidative stress
iomarkers for predicting cardiovascular mortality. Myeloperoxidase (MPO), nitrotyrosine,
xidized low-density lipoprotein, and C-reactive protein (CRP) were measured in a
rospective cohort of 885 subjects who underwent selective coronary angiography. During 13
ears of follow-up, MPO independently predicted coronary artery disease, and top tertile
PO levels predicted a 2.4-fold risk of cardiovascular mortality, compared to patients with
he lowest tertile MPO levels. Patients with elevated MPO or CRP levels had 5.3-fold
igher cardiovascular mortality risk; patients with high levels of both had a 4.3-fold higher
isk compared to those with only 1 elevated marker. Measuring MPO and CRP together
ay improve long-term cardiac risk assessment.ARDIAC IMAGING1110What Is the “Warranty Period” for a Normal CAC Scan?ames K. Min, Fay Y. Lin, David S. Gidseg, Jonathan W. Weinsaft, Daniel S. Berman, Leslee J. Shaw,
lan Rozanski, Tracy Q. Callister
coronary artery calcium (CAC) scan can identify the presence or absence of atherosclerosis,
ut little is known regarding the temporal “warranty period” of a normal scan. Min and
olleagues assessed the frequency of progression and time to progression of CAC in 422
atients with no baseline CAC (CAC  0). All subjects underwent annual CAC scanning
or 5 consecutive years. One-fourth of subjects developed CAC during follow-up. The
ncidence of conversion to CAC 0 was nonlinear and was highest in the fifth year. Among
atients with a normal baseline CAC scan, the rate of conversion to an abnormal CAC scan
ccurs at a low frequency before 4 years of follow-up.ditorial Comment: Harvey S. Hecht, p. 1118EDIATRIC CARDIOLOGY1121Efficacy and Safety of Rosuvastatin for Children With Familial Hypercholesterolemiaans J. Avis, Barbara A. Hutten, Claude Gagné, Gisle Langslet, Brian W. McCrindle, Albert Wiegman,
udith Hsia, John J. P. Kastelein, Evan A. Stein
vis and colleagues evaluated the efficacy and safety of rosuvastatin in children with familial
ypercholesterolemia (FH). This study comprised a 12-week, double-blind, randomized,
lacebo-controlled trial, followed by a 40-week, open-label, titration-to-goal extension phase
n children, age 10 to 17 years, with FH. Compared with placebo, rosuvastatin 5, 10, and 20
g reduced low-density lipoprotein cholesterol (LDL-C) by 38%, 45%, and 50%,
espectively. With a maximum allowed dose of 20 mg, 40% achieved the treatment goal of
110 mg/dl. While some patients had a transient elevation in liver enzymes and creatine
inase, all resolved with either continued treatment or rechallenge. Rosuvastatin 20 mg daily
an safely reduce LDL-C by 50% in children with FH.(continued on page A-27)
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bYPERTROPHIC CARDIOMYOPATHY1127Mutations in ACTN2 Can Cause HCMhristine Chiu, Richard D. Bagnall, Jodie Ingles, Laura Yeates, Marina Kennerson, Jennifer A. Donald,
ika Jormakka, Joanne M. Lind, Christopher Semsarian
tudies have shown that hypertrophic cardiomyopathy (HCM) can be caused by one of over
50 different mutations in at least 13 different genes. However, only 50% of HCM patients
ave one of the identified mutations. Chiu and colleagues performed a genome-wide linkage
nalysis on a family of 23 subjects with familial HCM. This suggested a mutation in the area
f the alpha-actinin-2 (ACTN2) gene and further testing confirmed this. This gene was then
nalyzed in another 297 HCM probands and 3 other causative ACTN2 mutations were
dentified. This is the first genome-wide linkage analysis that shows mutations in ACTN2
ause HCM.ditorial Comment: J. Martijn Bos, Michael J. Ackerman, p. 1136LATELETS AND THROMBOSIS
1139ess Platelet Inhibition With Dual Antiplatelet Therapy
in Diabetics With Kidney Diseaseominick J. Angiolillo, Esther Bernardo, Davide Capodanno, David Vivas, Manel Sabaté, José Luis Ferreiro,
asafumi Ueno, Pilar Jimenez-Quevedo, Fernando Alfonso, Theodore A. Bass, Carlos Macaya,
ntonio Fernandez-Ortiz
ngiolillo and colleagues measured the impact of renal function on platelet reactivity in
atients with diabetes mellitus (DM). This was a cross-sectional, observational study in which
atients with DM on maintenance aspirin and clopidogrel therapy were studied for the
egree of platelet inhibition. Patients with moderate/severe chronic kidney disease (CKD)
GFR 60 ml/min) had significantly higher adenosine diphosphate- and collagen-induced
latelet aggregation compared to those without CKD. After adjustment for potential
onfounders, patients with moderate/severe CKD were 2.4 to 3.8 times more likely to have
igh platelet reactivity. In DM patients, impaired renal function is associated with reduced
lopidogrel-induced antiplatelet effects.LATELETS AND THROMBOSIS1147Arterial Thrombus Formation on Atherosclerotic Plaques Requires 2 Stepsrmin J. Reininger, Isabell Bernlochner, Sandra M. Penz, Catherine Ravanat, Peter Smethurst,
ichard W. Farndale, Christian Gachet, Richard Brandl, Wolfgang Siess
eininger and colleagues studied the initial mechanism of arterial thrombus formation
nduced by atherosclerotic plaques. Human atheromatous plaque material, obtained from
arotid endarterectomy samples, was exposed to blood or blood components. Platelet
ggregation and coagulation were measured under static and arterial flow conditions by
icroscopic and physiological techniques. Thrombus formation was found to occur in 2
iscrete steps. The rapid first phase was triggered by platelet glycoprotein VI adhesion onto
laque collagen. The second phase of coagulation started after a delay of 3 min with the
inding of thrombin and fibrin to the activated platelets, and was driven entirely by plaque
issue factor (TF). Coagulation occurred only in flow niches, with no evidence for a role of
lood-borne TF.
